| Does Mind Medicine MindMed (MNMD) Have the Potential to Rally 279.84% as Wall Street Analysts Expect? |
The mean of analysts' price targets for Mind Medicine MindMed (MNMD) points to a 279.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-05-13 15:01:01 |
Czytaj oryginał (ang.) |
| Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript |
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Stephanie Fagan - Chief Corporate Affairs Officer Rob Barrow - Chief Executive Officer Matt Wiley - Chief Commercial Officer Dan Karlin - Chief Medical Officer Conference Call Participants Madhu Yennawar - Leerink Partners Brian Abrahams - RBC Capital Markets Elaine Kim - Cantor Rudy Li - Chardan Sumant Kulkarni - Canaccord Genuity Michael Okunewitch - Maxim Group Operator Good morning, and welcome to the MindMed's First Quarter 2025 Financial Results and Corporate Update Webcast. Currently, all participants are in listen-only mode. |
seekingalpha.com |
2025-05-08 13:55:40 |
Czytaj oryginał (ang.) |
| MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates |
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its first quarter 2025 financial results and provided an update on business highlights. “We are proud to share that all three of our pivotal Phase 3 trials evaluating MM120 ODT in patients with GAD and MDD—Voyage, Panorama, and Emerge—are actively enrolling. Momen. |
businesswire.com |
2025-05-08 11:00:00 |
Czytaj oryginał (ang.) |
| MindMed to Report First Quarter 2025 Financial Results on May 8, 2025 |
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 8:00 a.m. ET on Thursday, May 8, 2025 to report financial results for the first quarter ended March 31, 2025, and discuss recent business updates. Listeners can register for the webcast via this link. Analysts wishing to partici. |
businesswire.com |
2025-04-24 11:00:00 |
Czytaj oryginał (ang.) |
| MindMed Announces New Employee Inducement Grants |
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 121,500 common shares of the Company (the "Options"), with an effective grant date of April 21, 2025. The Options have an exercise price. |
businesswire.com |
2025-04-21 20:01:00 |
Czytaj oryginał (ang.) |
| MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD) |
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that the first patient has been dosed in its Phase 3 Emerge study evaluating MM120 ODT, a proprietary, pharmaceutically optimized form of LSD for the treatment of MDD. Emerge will evaluate the efficacy and safety of MM120 ODT 100 µg versus placebo and is expected. |
businesswire.com |
2025-04-15 11:00:00 |
Czytaj oryginał (ang.) |
| MindMed Announces New Employee Inducement Grants |
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 88,950 common shares of the Company (the "Options"), with an effective grant date of March 24, 2025. The Options have an exercise price e. |
businesswire.com |
2025-03-24 18:01:00 |
Czytaj oryginał (ang.) |
| Mind Medicine (MindMed) Inc. (MNMD) Q4 2024 Earnings Call Transcript |
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q4 2024 Earnings Conference Call March 6, 2025 8:00 AM ET Company Participants Stephanie Fagan - Chief Corporate Affairs Officer Rob Barrow - CEO Dan Karlin - CMO Conference Call Participants Madhu Yennawar - Leerink Gavin Clark-Gartner - Evercore ISI Charles Duncan - Cantor Joel Beatty - Baird Rudy Li - Chardan Sumant Kulkarni - Canaccord Genuity Patrick Trucchio - HC Wainwright & Company Michael Okunewitch - Maxim Group Operator Good morning, and welcome to the Mind Medicine Fourth Quarter and Year-End 2024 Financial Results Corporate Update Conference Call. Currently, all participants are in listen-only mode. |
seekingalpha.com |
2025-03-06 14:10:23 |
Czytaj oryginał (ang.) |
| MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates |
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its fourth quarter and full year 2024 financial results and provided an update on business highlights. “2024 was a year of significant progress for MindMed. We successfully achieved several key milestones that have built momentum for multiple clinical readouts fro. |
businesswire.com |
2025-03-06 09:00:00 |
Czytaj oryginał (ang.) |
| Why Mind Medicine Stock Is Skyrocketing Today |
Mind Medicine (MNMD 15.66%) stock is seeing impressive gains Friday. The company's share price was up 16.9% as of 3:15 p.m. |
fool.com |
2025-02-14 17:35:00 |
Czytaj oryginał (ang.) |
| MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder |
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that the first patient has been dosed in Panorama, its second Phase 3 study evaluating MM120 ODT, a proprietary, pharmaceutically optimized form of LSD for the treatment generalized anxiety disorder (GAD). The Panorama study will evaluate the efficacy and safety o. |
businesswire.com |
2025-01-30 09:00:00 |
Czytaj oryginał (ang.) |
| Why Mind Medicine Stock Is Soaring Today |
Mind Medicine (MNMD 8.97%) stock is posting big gains in Tuesday's trading. The biotech company's share price was up 8.7% as of 2 p.m. |
fool.com |
2025-01-07 16:25:53 |
Czytaj oryginał (ang.) |
| MindMed Stock Skyrockets 94% Year to Date: What's Driving It? |
2024 was a transformational year for MNMD as it executed many important milestones. |
zacks.com |
2024-12-24 13:25:22 |
Czytaj oryginał (ang.) |
| 5 Biotech Breakthrough Stocks to Watch in 2025 |
After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as the head of Health and Human Services. |
zacks.com |
2024-12-23 12:40:34 |
Czytaj oryginał (ang.) |
| MindMed to Be Added to the Nasdaq Biotechnology Index |
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will be added to the Nasdaq Biotechnology Index (NBI), effective at market open on Monday, December 23, 2024. “2024 has been a transformational year for MindMed. We've successfully executed many important milestones, including raising approximately $250 million. |
businesswire.com |
2024-12-19 09:00:00 |
Czytaj oryginał (ang.) |
| MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD) |
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD), has been granted an Innovation Passport for the potential treatment of GAD under ILAP by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA). The Innovation Passport is the. |
businesswire.com |
2024-12-05 09:00:00 |
Czytaj oryginał (ang.) |
| MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy |
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Javier A. Muniz, M.D., as Vice President of Research and Development (R&D) Strategy. In his new role, Dr. Muniz will drive innovation and growth of MindMed's R&D operations as the Company prepares to initiate three Phase 3 studies of MM120 or. |
businesswire.com |
2024-12-03 09:00:00 |
Czytaj oryginał (ang.) |
| MindMed Announces New Employee Inducement Grants |
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 171,000 common shares of the Company (the "Options"), with effective grant dates of November 18, 2024 and December 2, 2024, depending on the a. |
businesswire.com |
2024-12-02 09:00:00 |
Czytaj oryginał (ang.) |
| Mind Medicine: No News = Good News |
Mind Medicine's share price has responded very strongly to a third quarter update that contained very little new information. The market appears to have moved to a bullish stance following confirmation that clinical timelines have not been changed. With a key competitor recently running into difficulties, Mind Medicine may now be the favored play in the psychedelics sector. |
seekingalpha.com |
2024-11-10 11:55:00 |
Czytaj oryginał (ang.) |
| Mind Medicine (MindMed) Inc. (MNMD) Q3 2024 Earnings Call Transcript |
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Stephanie Fagan – Chief Corporate Affairs Officer Rob Barrow – Chief Executive Officer Dan Karlin – Chief Medical Officer Conference Call Participants Madhu Yennawar – Leerink Partners James Nevin – RBC Capital Markets Charles Duncan – Cantor Francois Brisebois – Oppenheimer Patrick Trucchio – H.C. Wainwright Michael Okunewitch – Maxim Group Sumant Kulkarni – Canaccord Genuity Operator Good afternoon, and welcome to Mind Medicine Third Quarter 2024 Financial Results and Corporate Update Conference Call. |
seekingalpha.com |
2024-11-07 22:06:14 |
Czytaj oryginał (ang.) |
| Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate |
Mind Medicine (MindMed) Inc. is advancing MM-120 for GAD with two phase 3 trials, VOYAGE and PANORAMA, starting in late 2024 and early 2025. MM-120 is also being tested for MDD in the phase 3 EMERGE study, starting in the first half of 2025, with data expected in late 2026. The company has secured funding through 2027, following a public offering, and burns approximately $24.5 million in cash per quarter. |
seekingalpha.com |
2024-11-04 18:04:19 |
Czytaj oryginał (ang.) |
| Psychedelic Stocks: Focus On Their Cash |
Jason Najum covers the psychedelic space and contextualizes recent news around the FDA, MDMA, PTSD, and Lykos Therapeutics. Why it may be a blessing in disguise for Cybin, COMPASS Pathways, and MindMed despite setbacks. |
seekingalpha.com |
2024-08-15 16:30:00 |
Czytaj oryginał (ang.) |
| Mind Medicine (MindMed) Inc. (MNMD) Q2 2024 Earnings Call Transcript |
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q2 2024 Earnings Conference Call August 13, 2024 8:00 PM ET Company Participants Robert Barrow - CEO Daniel Karlin - CMO Reid Robison - Senior Principal Investigator, Cedar Clinical Research Conference Call Participants Elaine Kim - Cantor Fitzgerald Brian Abrahams - RBC Capital Markets Rudy Li - Leerink Partners LLC Daniel Hultberg - Oppenheimer Christopher Chen - Robert W. Baird Sumant Kulkarni - Canaccord Genuity Operator Good morning, and welcome to the Mind Medicine Second Quarter 2024 Financial Results and Corporate Update Conference Call. |
seekingalpha.com |
2024-08-13 15:21:04 |
Czytaj oryginał (ang.) |
| MindMed readying Phase III trials for LSD therapy to treat anxiety |
MindMed Inc. MNMD, -0.87% said Tuesday it's on track to launch Phase 3 clinical trials with up to 440 people starting later this year for its treatment of generalized anxiety disorder (GAD) through use of lysergide D-tartrate (LSD) in a clinical setting. MindMed is working on FDA approval for an anxiety therapy using LSD. |
marketwatch.com |
2024-08-13 11:44:00 |
Czytaj oryginał (ang.) |
| Pacific Defense Announces US Army CMFF Program Team |
EL SEGUNDO, Calif.--(BUSINESS WIRE)--Pacific Defense, a leading provider of Modular Open Systems Approach (MOSA) products and mission solutions, announced their team to compete for the U.S. Army's CMOSS Mounted Form Factor (CMFF) program. Led by Pacific Defense, the CMFF team includes state-of-the-art industry technology leaders Thales Defense & Security Inc., BAE, Regal Technology Partners, Palantir and STC, an Arcfield Company. “Our company is purpose-built to drive the open-systems chang. |
businesswire.com |
2024-08-13 11:01:00 |
Czytaj oryginał (ang.) |
| FDA Rejection of MDMA Therapy Isn't End of Psychedelic-Drug Candidates |
The Food and Drug Administration rejected Lykos' application to treat PTSD with MDMA therapy. Atai, Compass Pathways, and MindMed are sliding in the wake of the decision. |
barrons.com |
2024-08-12 16:47:00 |
Czytaj oryginał (ang.) |
| Psychedelic drug contender stocks drop after FDA rejects MDMA treatment |
Shares of companies developing treatments based on psilocybin and other psychedelic drugs moved lower on Monday after the U.S. Food and Drug Administration rejected use of MDMA for post-traumatic stress disorder. |
marketwatch.com |
2024-08-12 16:12:00 |
Czytaj oryginał (ang.) |
| Mind Medicine (MindMed) Inc. Announces Proposed Public Offering |
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it intends to offer and sell, subject to market conditions, common shares and, to certain investors, pre-funded warrants to purchase common shares in an underwritten public offering. All of the common shares and pre-funded warrants are being offered by MindMed. Min. |
businesswire.com |
2024-08-09 10:00:00 |
Czytaj oryginał (ang.) |
| MindMed And Other Psychedelic Stocks Brace For FDA's Decision On MDMA Therapy |
The FDA's decision on MDMA therapy for PTSD is imminent, impacting MindMed investors and the psychedelic medicine industry. An FDA advisory committee voted against approving MDMA therapy, causing market volatility and uncertainty for psychedelic stocks. Major psychedelic stocks like MindMed have the fundamentals and growing FDA support to withstand a negative FDA decision on MDMA therapy. |
seekingalpha.com |
2024-08-07 18:29:10 |
Czytaj oryginał (ang.) |
| 3 Psychedelic Stocks to Ride to the Moon and Beyond |
The value of the psychedelic market is expected to approximately triple over the next few years. While not a large market in absolute terms, that growth potential will create many winning stocks. |
investorplace.com |
2024-07-06 11:21:00 |
Czytaj oryginał (ang.) |
| FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals |
The biotech industry has fallen on hard times over the last few years, no thanks to venture capital drying up, tighter regulatory conditions and the harsh reality of the post-pandemic healthcare environment. As a result, biotech breakthrough stocks fell out of favor with investors and were among the worst performers in the stock market. |
investorplace.com |
2024-07-04 18:13:23 |
Czytaj oryginał (ang.) |
| MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference |
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company's management team will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference being held on June 27, 2024. A webcast of the fireside chat will be accessible on MindMed's Investor Relations website starting on June 27,. |
businesswire.com |
2024-06-21 11:00:00 |
Czytaj oryginał (ang.) |